Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Neoplasms 2Triple Negative Breast Neoplasms 1Solid Tumors 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lung Neoplasms 1Hematologic Diseases 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1

Interventions

Fluorouracil 11Gemcitabine 8pembrolizumab 7Leucovorin 7Irinotecan 7Paclitaxel 6Oxaliplatin 5Carboplatin 5130-nm albumin-bound paclitaxel 5Nivolumab 4Cisplatin 4Albumin-Bound Paclitaxel 4Taxes 3Ramucirumab 3Radiosurgery 3Pemetrexed 3Docetaxel 3Capecitabine 3Bevacizumab 3vandetanib 2spartalizumab 2selinexor 2osimertinib 2folfirinox 2Radiation 2Cyclophosphamide 2zolbetuximab 1trastuzumab deruxtecan 1trametinib 1tofacitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Adenocarcinoma × LCL161 × Clear all
NCT02890069 2023-01-11

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Novartis

Phase 1 Completed
298 enrolled
BreastGastrointestinalGenitourinaryThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡